Please assess the completion status of the following clinical trial:

Trial Title: 12 Versus 20 mL PCB for D&E Cervical Prep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women 18 and older~* Intrauterine pregnancy ≥16 weeks gestation~* English speaking competency~* Willing and able to sign consent forms~* Agree to comply with study procedures~Exclusion Criteria:~* Women less than 18 years of age~* IV conscious sedation~* Known allergy to study medication (lidocaine)~* Any women not meeting inclusion criteria above will be excluded from participation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 12 mL arm (Type: EXPERIMENTAL): Intervention:~* Syringe loaded with 12 mL of 1% lidocaine (120 mg); 22-gauge spinal needle~* 2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix~* The tenaculum is immediately placed at the previously injected site~* The remaining 10 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)~* No wait time between injection and dilator insertion
- 20 mL arm (Type: ACTIVE_COMPARATOR): Intervention:~* Syringe loaded with 20 mL of 1% lidocaine (120 mg); 22-gauge spinal needle~* 2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix~* The tenaculum is immediately placed at the previously injected site~* The remaining 18 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)~* No wait time between injection and dilator insertion

Based on this trial design, predict the completion outcome and termination type (if applicable).